Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.

@article{Cunningham2008CotargetingTE,
  title={Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.},
  author={Matthew Paul Cunningham and H. K. Ng Thomas and Christopher Marks and Margaret Green and Zhen Xing Fan and Helmout Modjtahedi},
  journal={International journal of oncology},
  year={2008},
  volume={33 5},
  pages={1107-13}
}
The aberrant expression of the epidermal growth factor receptor (EGFR) has been reported in a wide range of epithelial tumours. In some studies, co-expression of insulin-like growth factor receptor-I (IGF-IR) have been associated with resistance to the EGFR inhibitors. Here, we investigated the sensitivity of a panel of human colorectal tumour cell lines, including two newly established lines Colo2 and Colo13, to treatment with anti-EGFR mAb ICR62 and IGF-IR tyrosine kinase inhibitor NVP-AEW541… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Targeting the IGF-1 receptor: from rags to riches.

European journal of cancer • 2004
View 10 Excerpts
Highly Influenced

The insulin-like growth factor system and cancer.

Cancer letters • 2003
View 10 Excerpts
Highly Influenced

EGFR targeting of solid tumors.

Cancer control : journal of the Moffitt Cancer Center • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…